Immunodeficient Mouse Expressing Human IL-15 for NK Cell Studies

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a need for mouse models that effectively support the study of human natural killer (NK) cells and interleukin 15 (IL-15)-dependent cell populations for research in human immunity, cancer, and infectious diseases, as mouse IL-15 cannot support the development of human NK cells, and existing models require additional factors like IL-15 receptor alpha.

Innovation Solution

An immunodeficient mouse genetically modified to express human interleukin 15 (hu-IL-15), lacking functional endogenous mouse NK cells, is engrafted with human hematopoietic stem cells or peripheral blood mononuclear cells, providing a model for assessing NK-cell mediated antibody-dependent cellular toxicity and IL-15-dependent processes without the need for additional factors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If mouse IL-15 is used in the mouse model, then the model is simple to maintain, but human NK cells cannot develop or survive

Engineering Contradiction:
Improvehuman NK cell development and survivalVSAvoidmodel complexity
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent changes the cytokine parameter from mouse IL-15 to human IL-15 in the mouse model system. This parameter change enables human NK cells to receive appropriate signaling for development and survival, resolving the incompatibility between mouse model simplicity and human cell functionality.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Human IL-15 acts as an intermediary substance that bridges the gap between the mouse model environment and human NK cell requirements. By introducing this intermediary cytokine, the model supports human cell development without requiring complex humanized immune system components.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Adaptability or versatility

If additional factors like IL-15 receptor alpha are supplied, then human NK cell development is supported, but the model complexity increases

Engineering Contradiction:
Improvehuman NK cell support capabilityVSAvoidnumber of required factors
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent extracts the essential requirement from the complex system of multiple factors (IL-15, IL-15Rα, etc.) and identifies that human IL-15 alone is sufficient to support human NK cell development. This extraction simplifies the model by removing unnecessary complexity while maintaining functionality.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

Human IL-15 serves multiple functions in the model: it acts as both the cytokine signal and the sole essential factor for human NK cell development and survival. This multi-functionality eliminates the need for additional factors like IL-15 receptor alpha supplementation.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If in vitro culture with human IL-15 is used, then human NK cells can be maintained, but repeated injections of recombinant IL-15 are required

Engineering Contradiction:
Improvehuman NK cell maintenanceVSAvoidfrequency of injections
Core Design Contradiction:
Adaptability or versatilityVSLoss of time

Solution Approach 1:

The mouse model expresses human IL-15 endogenously, enabling it to self-produce the necessary cytokine for human NK cell maintenance. This self-service capability eliminates the need for external supplementation through repeated injections, as the model sustains itself autonomously.

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The model is pre-configured with human IL-15 expression capability before human NK cells are introduced. This preliminary action ensures that the cytokine is already available in the model environment, eliminating the need for subsequent repeated injections to maintain human NK cells.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP3664603B1Immunodeficient mice expressing human interleukin 15
Publication Date: 2024.01.03 JACKSON LAB THE
  • EP3664603B1 patent drawingFigure 1
  • EP3664603B1 patent drawingFigure 2
  • EP3664603B1 patent drawingFigure 3

AI summary

An immunodeficient mouse is provided which is useful as a model of functions and regulation of human natural killer (NK) cells and other interleukin 15 (IL-15)-dependent cell populations and processes in studies of human immunity, cancer, infectious diseases, and other areas. According to specific aspects, an immunodeficient mouse is provided which is genetically modified to express human interleukin 15, wherein the mouse does not have or produce functional mouse natural killer cells, and wherein the mouse is modified to include human natural killer cells. Methods of identifying anti-tumor activity of a test substance using a mouse of the present invention are described along with methods of making the mouse.